Nucleic Acid News and Research

RSS

Two fully automated molecular testing systems for blood and plasma donor screening launched by Roche

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the commercial availability of the cobas 6800/8800 Systems, two integrated and fully automated molecular testing systems for blood and plasma donor screening, in markets accepting the CE mark. The cobas 6800/8800 Systems offer the fastest time to results with the highest throughput available, along with the longest walk-away time, enabling laboratory staff to drive increased workflow efficiencies, while adapting to their ever-changing testing demands.

From Roche Sequencing and Life Science 2 Sep 2014

BioTek continues to set the standard in microplate instrumentation

BioTek continues to set the standard in microplate instrumentation by designing practical functionality, user-friendly software, and affordable modularity as seen in the new Synergy™ HTX Multi-Mode Microplate Reader. This new system is offered as an entry-level multi-mode reader to automate UV-Vis absorbance, fluorescence, luminescence and AlphaScreen®/AlphaLISA® assays in 6- to 384-well microplates in 2 µL samples with BioTek’s Take3 Micro-Volume plates.

15 Aug 2014

Combination of NASBA and real-time qPCR detects aspergillosis with 100% accuracy

The fungal infection invasive aspergillosis (IA) can be life threatening, especially in patients whose immune systems are weakened by chemotherapy or immunosuppressive drugs. Despite the critical need for early detection, IA remains difficult to diagnose.

14 Aug 2014

ISO 13485:2003 certification for Advanced Cell Diagnostics

Advanced Cell Diagnostics, Inc. (ACD), a global technology and market leader in in situ nucleic acid detection for life science research and clinical diagnostics, has been granted ISO 13485:2003 certification, an international quality standard for medical devices, paving a path for ACD to launch its CE marked diagnostic tests in Europe.

From Advanced Cell Diagnostics 11 Aug 2014

Idera collaborates with TMA to advance new potential treatment approach for myositis

Idera Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing nucleic acid therapeutics for patients with cancer and rare diseases, and The Myositis Association (TMA), the only nonprofit organization dedicated to solely serving all patients with inflammatory myopathies, today announced a collaboration to advance a new potential treatment approach for polymyositis and dermatomyositis known as Toll-like receptor (TLR) antagonism.

7 Aug 2014

Celsion announces financial results for second quarter ended 2014

Celsion Corporation, an oncology drug development company, today announced financial results for the second quarter ended June 30, 2014.

7 Aug 2014

WIRB-Copernicus Group acquires Alliance Biosciences

WIRB-Copernicus Group, the world's largest provider of regulatory and ethical review services for clinical research, announced today that it has acquired Alliance Biosciences. Formerly a division of Richmond, VA-based Alliance Engineering, Alliance Biosciences was the leading biosafety and biosecurity consulting firm in the United States.

24 Jul 2014

National Gay Blood Drive to take place on July 11, 2014

On Friday, July 11, the second annual nationwide National Gay Blood Drive (NGBD) will take place to raise public awareness and increase pressure on the U.S. Food and Drug Administration (FDA) to change its policy on the long-standing ban on blood donation by men who have had sex with other men (MSM) – a restriction that has been in place since 1983.

10 Jul 2014

Scientists release recommendations for evaluating pharmacological safety of oligonucleotide therapeutics

Novel oligonucleotide-based drugs in development offer promising alternatives for treating a range of diseases.

8 Jul 2014

Fabry disease awareness: an interview with Dr. Hartmann Wellhoefer, Head of Medical Affairs, Rare Disease, Shire

Lysosomes are subcellular organelles that are present in most cells, with the major exception of red blood cells.

8 Jul 2014

BINDER ultra low temperature freezer provides high safety for biological samples

In the field of cell biology in particular, a wide variety of samples including nucleic acid or protein samples have to be preserved for longer periods of time. At temperatures down to – 86°C, samples often remain frozen for several weeks up to several years. 100% reliability of the cooling system is essential. Otherwise, any interruption could result in the complete loss of the research results, requiring the results to be recreated, which costs time and money.

From BINDER GmbH 3 Jul 2014

Eurofins Genomics, AmpTec sign co-marketing agreement for IVT-RNAs

Eurofins Genomics, international market leader in genomic services, and AmpTec, internationally recognized provider of RNA technology products, have agreed on non-exclusively co-marketing AmpTec's IVT-RNAs globally.

2 Jul 2014

Celsion acquires all assets of EGEN

Celsion Corporation, an oncology drug development company, today announced the completion of the acquisition by Celsion of substantially all of the assets of EGEN, Inc., a privately-held biopharmaceutical company focused on the development of nucleic acid-based therapeutics for the treatment of cancer and other difficult to treat diseases.

21 Jun 2014

Celsion signs definitive asset purchase agreement to acquire EGEN

Celsion Corporation (Celsion) (NASDAQ: CLSN), an oncology drug development company, and EGEN, Inc. (EGEN), a privately-held biopharmaceutical company focused on the development of nucleic acid-based therapeutics for the treatment of cancer and other difficult to treat diseases, today announced the signing of a definitive asset purchase agreement in which Celsion will acquire substantially all of the assets of EGEN, including its Phase Ib DNA-based immunotherapy product candidate EGEN-001 and its therapeutic platform technologies, TheraPlas™ for delivery of DNA and mRNA, TheraSilence™ for delivery of RNA, and RAST™ for Cell Enabled Expression and Secretion of RNA.

10 Jun 2014

Co-founder of Avidity Nanomedicines to receive 2014 Prince of Asturias Award

Avidity NanoMedicines LLC, a biopharmaceutical company pioneering a breakthrough approach to the targeted delivery of nucleic acid-based medicines, announced today that its scientific co-founder, Mark E. Davis, Ph.D., will receive the 2014 Prince of Asturias Award for Technical and Scientific Research.

9 Jun 2014

Rice develops highly accurate test to detect signs of HIV

Rice University bioengineers are developing a simple, highly accurate test to detect signs of HIV and its progress in patients in resource-poor settings.

6 Jun 2014

Study: RNAi silencing strategy blocks production of mutant huntingtin protein

A targeted gene silencing strategy blocks production of the dysfunctional huntingtin (Htt) protein, the cause of Huntington's disease, a fatal, inherited neurodegenerative disorder.

22 May 2014

Bio-Path Holdings reports net loss of $504,876 for first quarter 2014

Bio-Path Holdings, Inc., a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced operational and financial results for the first quarter ended March 31, 2014.

17 May 2014

Protein Data Bank now contains over 100,000 structures

Spanning the globe from the US, UK, and Japan, the Worldwide Protein Data Bank (wwPDB) organization announces that the Protein Data Bank archive now contains more than 100,000 entries.

14 May 2014

DFG German Research Foundation to establish 16 new Priority Programs

The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) will establish 16 new Priority Programmes, in which researchers will investigate fundamental scientific questions in particularly topical or emerging areas of research over the next few years.

4 Apr 2014